This trial will test a combo of drugs for early-stage NSCLC to see if it can safely and effectively treat the disease.
- Non-Small Cell Lung Cancer
2 Primary · 8 Secondary · Reporting Duration: Up to approximately 2 years.
1 Treatment Group
IPH5201 + durvalumab + standard chemotherapy
1 of 1
70 Total Participants · 1 Treatment Group
Primary Treatment: IPH5201 + durvalumab + standard chemotherapy · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many participants are being included in the research endeavor?
"Affirmative. The details provided on clinicaltrials.gov verify that this research trial, which was first publicized in February 1st 2023, is actively soliciting participants. Approximately 70 subjects must be enlisted from two distinct centres of care." - Anonymous Online Contributor
Is this research initiative currently accepting new participants?
"According to the clinicaltrials.gov website, this medical trial is currently open for enrollment and was initially announced on February 1st 2023 with its last update taking place on February 23rd of that same year." - Anonymous Online Contributor
Has the combination of IPH5201, durvalumab and standard chemotherapy been endorsed by the FDA?
"Our team's evaluation graded the safety of IPH5201 + durvalumab + standard chemotherapy at 2 out of 3 due to only Phase 2 trial results being available and no existing evidence for efficacy." - Anonymous Online Contributor
What are the distinct ambitions of this clinical trial?
"Innate Pharma, the trial sponsor of this medical study, has indicated that Adverse events (AEs) and Serious adverse Events (SAEs) will be measured as primary outcomes over a 16 week period post-first dose. Additionally, Disease Free Survival (DFS), Surgical Resection, and Anti-study Drug Antibodies (ADA) are noted as secondary outcomes for measurement purposes." - Anonymous Online Contributor